{"version":"1.0","provider_name":"Cancer Research Institute","provider_url":"https:\/\/www.cancerresearch.org\/es","title":"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ent3XZqhaJ\"><a href=\"https:\/\/www.cancerresearch.org\/es\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\">La combinaci\u00f3n de f\u00e1rmacos gana terreno en el desarrollo de la inmunooncolog\u00eda de los ensayos cl\u00ednicos con inhibidores de PD-1 y PD-L1, seg\u00fan un nuevo informe del Cancer Research Institute\ufffc<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.cancerresearch.org\/es\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\/embed#?secret=Ent3XZqhaJ\" width=\"600\" height=\"338\" title=\"\u00abLa combinaci\u00f3n de f\u00e1rmacos gana terreno en el desarrollo de la inmunooncolog\u00eda de los ensayos cl\u00ednicos con inhibidores de PD-1 y PD-L1, seg\u00fan un nuevo informe del Cancer Research Institute\ufffc\u00bb \u2014 Cancer Research Institute\" data-secret=\"Ent3XZqhaJ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.cancerresearch.org\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg","thumbnail_width":700,"thumbnail_height":500,"description":"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials."}